Presenter's Information

Akiko Maehara, MD

Country USA
Specialty Interventional Cardiologist
  1. Next Promising Novel Imaging Techniques for Vulnerable Plaques
  2. Mechanism of Left Main Stent Failure
  3. Risk Stratification of PCI-Related Hematoma
  4. Evolution of Calcified Plaque
  5. Chronic Stent Recoil: An Emerging Mechanism of In-Stent Restenosis
  6. Calcified Nodules in Complex PCI: Are They All the Same and How Should We Treat?
  7. AI for Imaging and Physiology Interpretation
  8. What Is a Vulnerable Plaque? Insights From Invasive Intravascular Imaging
  9. Prediction of Stent Expansion by IVUS and OCT
  10. Reclassification of Vulnerable Plaque Including Intraplaque Hemorrhage, Fissure, Healed Plaque and More
  11. Understanding MINOCA: Lessons and Case Examples from the HARP Registry
  12. Mechanical Issue of Left Main Stenting - Gap, Incomplete Crush, Deformation and More
  13. Year-In-Review: Intracoronary Imaging & Physiology
  14. Prepare & Predict: Role of Intracoronary Imaging for Calcified Lesion PCI
  15. Imaging Guidance for Calcified Lesion PCI
  16. Intravascular Imaging for Guidance of Plaque Modification Strategies in Calcified Coronary Artery
  17. The Role of Imaging in Calcified Lesions
  18. Coronary Imaging Perspective
  19. [Vulnerable Plaque Detection: What Is New in 2018?] NIRS
  20. Prognosis of "Yellow" Plaque In NIRS
  21. OCT-Guided PCI: OPINION, DOCTORS, ILUMIEN-III and ILUMIEN-IV
  22. How IVUS Improve LM and Bifurcation Outcomes?
  23. ILLUMEN-3 and Others: Imaging-Guided PCI Optimization
  24. How May Imaging Help in LM PCI?
  25. Differences in Plaque Morphology and Stability in STEMI, NSTE-ACS and Stable CAD
  26. Lessons from EXCEL IVUS Substudy
  27. Current and Future Imaging Diagnosis of Vulnerable Plaque
  28. New Findings from COLOR Registry
  29. Difference Between Coronary Artery Disease and Peripheral Artery Disease
  30. Clinical Utility of High-Resolution IVUS
  31. Do Malapposition, Stent Deformation and Fracture Link to Worse Clinical Outcome?
  32. Imaging Criteria of Vulnerable Plaques
  33. Vulnerable Plaque Detection by Grayscale IVUS and NIRS
  34. State-of-the-Art in High Resolution IVUS
  35. Clinical Trials by Using NIRS: Clinical Relevance and Prognostic Implication
  36. Beyond IVUS: OCT, NIRS, and Beyond
  37. NIR: PROSPECT II and PROSPECT ABSORB Trial
  38. NIRS-IVUS to Predict Long Term Outcome
  39. It Is Time for Practical Use of High-resolution IVUS
  40. Role of IVUS and OCT in Left Main PCI
  41. IVUS-Guided PCI: ADAPT-DES and More...
  42. NIR Spectroscopy: Fundamentals and Diagnostic Applications
  43. Beyond IVUS: OCT, NIRS, and Beyond
  44. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - Yes, I Do. It Will Save Lives and Prevent ACS.
  45. Combined IVUS-NIR Spectroscopy: How to Predict Vulnerable Plaque and PCI Outcome
  46. High Resolution IVUS: See the Unseen!
  47. VH-IVUS: Native Vessel and Neointima
  48. IVUS: Pre-intervention and Post-intervention
  49. Various Types of Yellow Plaque Evaluated by NIRS/IVUS Catheter
  50. NIR
  51. IVUS: Postintervention
  52. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Like to Treat
  53. Near Infrared Spectroscopy
  54. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] Yes, I Do
  55. Neoatherosclerosis: Something New or Nothing New?
  56. [Does Morphology Predict Future Events?] Pro: Yes, Insights from PROSPECT
  57. IVUS Guided CTO Intervention
  58. Morphology and Distribution of Left Main and Non Left Main Bifurcation Atherosclerosis
  59. How Are Left Main and Non Left Main Bifurcations Unique: Insights from Imaging
  60. Temporal Stability of Focal Plaques: 2012 Imaging Insights
  61. Optical Coherence Tomography During PCI: A Research Tool or a Valued Clinical Asset?
  62. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] No, >0.80 Is Not Enough.
  63. Application of the 2nd Generation OCT in LM PCI
  64. Angioscopic and VH Characteristics of Culprits in ACS Patients
  65. What Would Be the Optimal IVUS Criteria to Predict Functional Significance?
  66. When and How To Assess Morphology and Function and Why?
  67. Tissue Characterization Using VH-IVUS; Pitfalls and Artifacts
  68. Expert Opinion for IVUS Use in Practice (Several IVUS Registry and PROSPECT Trial)
  69. Cardiovascular Imaging: “When/How/Which Imaging Modality Should We Choose?”
  70. IVUS Interpretation and Measurement: Focusing on What Important
  71. Assessment of Vulnerable Plaque by IVUS and VH-IVUS
  72. Role of MDCT in PCI Planning: Focus on CTO Treatment
  73. Limitations of IVUS: Why We Need Newer Imaging Techniques
Conference Slides
Category